This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Efficacy of acatinol memantine in mild cognitive disorder


Levin, O. S., Iunishchenko, N. A., Dudarova, M. A.


Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova / Ministerstvo Zdravookhraneniia I Meditsinskoĭ Promyshlennosti Rossiĭskoĭ Federatsii, Vserossiĭskoe Obshchestvo Nevrologov [I] Vserossiĭskoe Obshchestvo Psikhiatrov, Volume: 109, No.: 7, Pages.: 36-42

Year of Publication



An open 6 month clinical trial of efficacy of acatinol has been carried out in patients with mild cognitive disorder (MCD). Forty patients received acatinol and 20 patients of comparison group were treated with piracetam. Mean age of patients was 67,7+/-7,2 years. Patient’s state was assessed with a battery of scales, questionnaires and neuropsychological tests. Acatinol was prescribed in dosage 10 mg daily and piracetam in dosage 1200 mg daily at baseline, after 3 and 6 months of treatment. Thirty-eight (95%) of patients treated with acatinol and 18 (90%) of patients treated with piracetam have completed the treatment. In the acatinol group, worsening was seen in 5% of patients, no changes – in 20%, moderate improvement – in 35%, marked improvement – in 25%, substantial improvement – in 15%. Portion of patients with worsening or absence of changes was significantly lower and that with marked and substantial improvement was higher in the acatinol group compared to the piracetam group. The global assessment of cognitive functions on the MMSE scale was significantly increased to the end of 3rd month in both groups. However this improvement was maintained to the end of 6th month only in patients treated with acatinol. In the latter group, the positive changes of depressive symptoms, subjective symptoms and quality of life were shown. The positive dynamics was more pronounced in patients with dysregulation type of MCD compared to patients with amnesic type. The authors suggest a term <>. For this type of MCD the use of acatinol may be most necessary.;


acatinol, administration & dosage, aged, aged, 80 and over, cognition, cognition disorders, drug effects, drug therapy, excitatory amino acid antagonists, female, humans, male, memantine, middle aged, neuroprotective agents, physiopathology, piracetam, questionnaires, therapeutic use, treatment outcome

Types of Dementia

Mild Cognitive Impairment (MCI)

Types of Study

Non randomised controlled trial

Type of Outcomes

Cognition, Depression and Anxiety, Quality of Life of Person With Dementia

Type of Interventions

Pharmaceutical Interventions

Pharmaceutical Interventions

Anti-Alzheimer medications, e.g.: donezepil, galantamine, rivastigmine, memantime